GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Enterprise Value

Traws Pharma (Traws Pharma) Enterprise Value : $-0.69 Mil (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Traws Pharma's Enterprise Value is $-0.69 Mil. Traws Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.37 Mil. Therefore, Traws Pharma's EV-to-EBIT ratio for today is 0.04.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Traws Pharma's Enterprise Value is $-0.69 Mil. Traws Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.36 Mil. Therefore, Traws Pharma's EV-to-EBITDA ratio for today is 0.04.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Traws Pharma's Enterprise Value is $-0.69 Mil. Traws Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.23 Mil. Therefore, Traws Pharma's EV-to-Revenue ratio for today is -3.04.


Traws Pharma Enterprise Value Historical Data

The historical data trend for Traws Pharma's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Enterprise Value Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.85 67.59 -1.79 -25.25 -5.16

Traws Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.90 -4.98 -10.30 -5.16 4.91

Competitive Comparison of Traws Pharma's Enterprise Value

For the Biotechnology subindustry, Traws Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Enterprise Value falls into.



Traws Pharma Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Traws Pharma's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Traws Pharma's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Traws Pharma  (NAS:TRAW) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Traws Pharma's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-0.686/-19.373
=0.04

Traws Pharma's current Enterprise Value is $-0.69 Mil.
Traws Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.37 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Traws Pharma's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-0.686/-19.356
=0.04

Traws Pharma's current Enterprise Value is $-0.69 Mil.
Traws Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.36 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Traws Pharma's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-0.686/0.226
=-3.04

Traws Pharma's current Enterprise Value is $-0.69 Mil.
Traws Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Traws Pharma Enterprise Value Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (Traws Pharma) Business Description

Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

Traws Pharma (Traws Pharma) Headlines